Health
Bayer’s Lynkuet® (elinzanetant), the First and Only Neurokinin 1 and Neurokinin 3 Receptor Antagonist, Receives FDA Approval for Moderate to Severe Hot Flashes Due to Menopause
WHIPPANY, N.J., October 24, 2025--Bayer announced today the U.S. Food and Drug Administration (FDA) has approved Lynkuet® (elinzanetant) 60mg capsules, the first and only dual neurokinin (NK) targeted therapy,1 neurokinin 1 (NK1) and neurokinin 3 (NK3) receptor antagonist, for the treatment of moderate to severe hot flashes due to menopause.1 Inhibition of Substance P and Neurokinin B through antagonism of NK1 and NK3 receptor signaling on kisspeptin/neurokinin B/dynorphin (KNDy) neurons can mod
About this update from Bayer Ag
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":400,"url":"https://media.zenfs.com/en/business-wire.com/9064c34a7c4c835e12da028c38e173ee"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/9iLTVEkAZp8ds8cjRHYukQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTcwNTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/9064c34a7c4c835e12da028c38e173ee","width":400,"height":400}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"This approval is supported by data from the Phase III OASIS clinical trial program evaluating Lynkuet for the treatment of moderate to severe hot flashes due to menopause1","length":171,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"In OASIS 1 and OASIS 2, Lynkuet met the co-primary endpoints of reduction in number and severity of moderate to severe hot flashes day and night at weeks 4 and 12 from baseline1","length":177,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Hot flashes are a common symptom of menopause2 and one of the main reasons women seek treatment;3 hot flashes may impact women differently4 and some can be disruptive5","length":167,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":515,"olType":false},{"type":"text","content":"WHIPPANY, N.J., October 24, 2025--(BUSINESS WIRE)--Bayer announced today the U.S. Food and Drug Administration (FDA) has approved Lynkuet® (elinzanetant) 60mg capsules, the first and only dual neurokinin (NK) targeted therapy,1 neurokinin 1 (NK1) and neurokinin 3 (NK3) receptor antagonist, for the treatment of moderate to severe hot flashes due to menopause.1 Inhibition of Substance P and Neurokinin B through antagonism of NK1 and NK3 receptor signaling on kisspeptin/neurokinin B/dynorphin (KNDy) neurons can modulate neuronal activity in the thermoregulation associated with hot flashes.1 Lynkuet soft gel capsules are taken once daily at bedtime, with or without food.1 The FDA approval is supported by data from three Phase III clinical trials (OASIS 1, OASIS 2 and OASIS 3) that evaluated the safety and efficacy of Lynkuet for the treatment of moderate to severe hot flashes due to menopause.1","length":903,"tagName":"p"},{"type":"text","content":""The FDA approval of Lynkuet is an important new option for...